CYP2C19 genotype and the PPIs - Focus on rabeprazole

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue SUPPL. 3, 2005, Pages

  Lim, P W Y ^a   Goh, K L ^b   Wong, B C Y ^c  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acid related disorders; Consistent inhibition; CYP4502C19 genetic polymorphism; Rabeprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; METRONIDAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ADENOSINE TRIPHOSPHATASE; ANTIULCER AGENT; BENZIMIDAZOLE DERIVATIVE; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; MIXED FUNCTION OXIDASE; OMEPRAZOLE; PROTON PUMP; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNSPECIFIC MONOOXYGENASE;

ASIA; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ERADICATION THERAPY; ETHNIC GROUP; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SOUTHEAST ASIA; STOMACH ACID SECRETION; STOMACH PH; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; ETHNOLOGY; GENETICS; METABOLISM; PH; REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE TRIPHOSPHATASES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON PUMPS; PROTON-TRANSLOCATING ATPASES;

EID: 33645923112     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04167.x     Document Type: Conference Paper

References (40)

1. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int. J. Clin. Pract. 2005; 59: 709-15.
2. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 2001; 52: 349-55.
3. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999; 13 (Suppl. 3): 27-36.
4. Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J. Gastroenterol. Hepatol. 2001; 13 (Suppl. 1): S43-7.
5. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur. J. Gastroenterol. Hepatol. 2001; 13 (Suppl. 1): S29-33.
6. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 1994; 269: 15419-22.
7. Kubota T, Chiba K, Ishizaki T. Genotyping of Smephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 1996; 60: 661-6.
8. Abelo A, Andersson TB, Bredberg U, Skanberg I, Weidolf L. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab. Dispos. 2000; 28: 58-64.
9. McColl KE, Kennerley P. Proton pump inhibitors - differences emerge in hepatic metabolism. Dig. Liver Dis. 2002; 34: 461-7.
10. Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. Aliment. Pharmacol. Ther. 2004; 20: (Suppl. 6): 1-10.
11. Rabeprazole US Package Insert. [Cited 01 August 2005] Available from: http://www.aciphex.com/aciphexpi.pdf
12. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther. 2004; 20: 99-107.
13. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539-49.
14. Yamada S, Onda M, Kato S et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 2001; 36: 669-72.
15. Yang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br. J. Clin. Pharmacol. 2004; 58: 332-5.
16. Tassaneeyakul W, Tawalee A, Tassaneeyakul W et al. Analysis of the CYP2C19 polymorphism in a Northeastern Thai population. Pharmacogenetics 2002; 12: 221-5.
17. Goldstein JA, Ishizaki T, Chiba K et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64.
18. Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995; 5: 64-71.
19. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6: 547-51.
20. He N, Yan FX, Huang SL et al. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. Eur. J Clin. Pharmacol. 2002; 58: 15-18. Epub 2002 Feb 22.
21. Fu LQ, Huang F, Wu DZ, Guo JH. Comparison of genetic polymorphism of cytochrome CYP2C19 between men and women in Chinese population. Yao Xue Xue Bao 2004; 39: 161-3.
22. Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 2000; 6: PL175-81.
23. Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J. Clin. Pharmacol. 2004; 44: 582-9.
24. Egan LJ, Murray JA. New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors. Dig. Dis. 2000; 18: 58-63.
25. Kita T, Sakaeda T, Baba T et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol. Pharm. Bull. 2003; 26: 386-90.
26. Furuta T, Ohashi K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 1999; 65: 552-61.
27. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000; 119: 670-6.
28. Adachi K, Katsube T, Kawamura A et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 2000; 14: 1259-66.
29. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002; 16: 1811-17.
30. Wang H, Nie YQ, Dai SJ, She QZ, Li YY. The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism. Zhonghua Nei Ke Za Zhi 2003; 42: 777-80.
31. Kita T, Sakaeda T, Aoyama N et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol. Pharm. Bull. 2002; 25: 923-7.
32. Takahisa F, Kyoichi O, Takashi K et al. Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer. Ann. Intern. Med. 1998; 129: 1027-30.
33. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. 2004; 76: 201-9.
34. Hokari K, Sugiyama T, Kato M et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther. 2001; 15: 1479-84.
35. Lee SB, Park SJ, Ryu JK et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J. Gastroenterol. 2003; 42: 468-75.
36. He XX, Zhao YH, Hao YT. Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese. Zhonghua Nei Ke Za Zhi 2004; 43: 13-15.
37. Kawamura M, Ohara S, Koike T et al. The effects of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 2003; 17: 965-73.
38. Furuta T, Shirai N, Watanabe F et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 2002; 72: 453-60.
39. Kinoshita Y. Review article: treatment for gastrooesophageal reflux disease - lifestyle advice and medication. Aliment. Pharmacol. Ther. 2004; 20 (Suppl. 8): 19-23.
40. Ariizumi K, Ohara S, Koike T Sr et al. The therapeutic effects of rabeprazole at a dose of 10 mg on reflux esophagitis may not be influenced by CYP2C19 polymorphism. Gastroenterology 2004; 126 (Suppl. 2): 340 (Abstract).